| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 27.7 | 29.4 |
| Profit before tax | -41.3 | -73.4 |
| Net income | -41.0 | -80.8 |
| EPS (diluted, $ a share) | $-0.64 | $-1.45 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -5.7% |
|---|---|
| Operating margin | -157.5% |
10-Q filed with the SEC, NYSE: DNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ginkgo Bioworks Holdings, Inc.: key numbers
- Share price
- $8.32Close, Nov 17
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ginkgo Bioworks Holdings, Inc.
All →Ginkgo Bioworks Holdings Financial Results
Ginkgo Bioworks reported Q3 2026 revenue of $28 million and a GAAP net loss of $41 million, showing improvement from the prior year's $73 million loss. The company highlighted the sale of its first autonomous lab to Novo and new government contracts with ARPA-H and the NSF as it transitions to a platform focused on Autonomous Labs and Cloud Lab services.
- Term
- Q3 2026
“Ginkgo now has two core offerings built on one autonomous lab platform. This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF. Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data. With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research.”
Jason Kelly, Co-founder and CEO of Ginkgo Bioworks
Ginkgo Bioworks Holdings Insider Reshma P. Shetty Sells $418K of Stock
Reshma P. Shetty sold 41,172 shares of Ginkgo Bioworks Holdings, Inc. at $10.14 a share, worth $418K in total on Oct 19, 2026. Shares held after the trade: 356,329 (-5.0%).
- Value
- $418K
- Shares
- 41,172
- Average price
- $10.14
- Holding change
- -5.0%
- Trade date
- Oct 19, 2026
Ginkgo Bioworks Holdings Insider Jason R. Kelly Sells $463K of Stock
Jason R. Kelly sold 45,682 shares of Ginkgo Bioworks Holdings, Inc. at $10.14 a share, worth $463K in total on Oct 19, 2026. Shares held after the trade: 129,065 (-26.1%).
- Value
- $463K
- Shares
- 45,682
- Price
- $10.14
- Holding change
- -26.1%
- Trade date
- Oct 19, 2026
Ginkgo Bioworks Holdings Insider Steven P. Coen Sells $36K of Stock
Steven P. Coen sold 2,403 shares of Ginkgo Bioworks Holdings, Inc. at $15.00 a share, worth $36K in total on Oct 5, 2026. Shares held after the trade: 49,448 (-4.6%).
- Value
- $36K
- Shares
- 2,403
- Price
- $15.00
- Holding change
- -4.6%
- Trade date
- Oct 5, 2026
Ginkgo Bioworks Holdings Insider Christian O. Henry Sells $35.4K of Stock
Christian O. Henry sold 5,000 shares of Ginkgo Bioworks Holdings, Inc. at $7.08 a share, worth $35.4K in total on Sep 15, 2026. Shares held after the trade: 19,310 (-20.6%).
- Value
- $35.4K
- Shares
- 5,000
- Price
- $7.08
- Holding change
- -20.6%
- Trade date
- Sep 15, 2026